Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab and Semi-Enteral Nutrition for Preoperative Optimization in Crohn's Disease
NCT06912815Recruiting
- Sponsor
- GemPharmatech
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by GemPharmatech. Primary endpoint: Preoperative clinical remission rate at 6 weeks. Started Aug 2024; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06912815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912815.